November 18, 2011—U.S. Sen. Orrin Hatch (R-Utah), the ranking Republican on the Senate Finance Committee and a senior member of the Health, Education, Labor and Pensions (HELP) Committee, reportedly is drafting legislation that would exclude “medically necessary” drugs that are in short supply from 340B discounts and Medicaid rebates for possibly up to three years, the Monitor has learned.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)